

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康集團

Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

POSITIVE PROFIT ALERT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Uni-Bio Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the latest unaudited consolidated management accounts of the Group for the year ended 31 December 2023 (the “**Year**”), the Group is expected to record a profit attributable to the owners of the parent of not less than HK\$60 million (2022: profit of HK\$38.51 million) for the Year.

Based on the information available to the Board, the Board considers such expected increase was mainly attributable to (1) an increase in sales revenue of not less than about 10% over that in 2022. The sales revenue in the same period of 2022 was HK\$440 million, and the increase in revenue was mainly due to the Company’s continuous expansion of hospital coverage and applicable patient population through academic promotion, which was fully recognised by the market and patients; (2) the Group continued to optimize and control production costs, continuously deepen cooperation with raw material suppliers, and reduce the procurement cost of the Active Pharmaceutical Ingredient; and (3) the Group achieved CMO revenue of more than HK\$9 million, representing an increase of not less than about 200% over corresponding period of 2022, or an increase of more than HK\$6 million.

* For identification purpose only

As at the date of this announcement, the Company is still in the course of preparing the annual results of the Group for the Year. The information contained in this announcement is only based on the preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group for the Year, which have not been reviewed by the Company's auditors or the audit committee of the Board. Such financial information will be subject to finalisation and necessary adjustments. The annual results of the Group for the Year are expected to be announced by the Company before the end of March 2024. Shareholders and potential investors are advised to read the annual results announcement of the Company when it is published.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 14 February 2024

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman) and Mr. Zhao Zhi Gang; one non-executive Director, Mr. Yau Kwok Wing Tony; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.